The treatment algorithms for MBC are mainly decided based on estrogen receptor (ER), progesterone receptor and ERBB2 receptor tyrosine kinase 2 (ERBB2/HER2) expression, assessed by immunohistochemistry (IHC) staining of the primary tumor. This evidence concerns the gene ERBB2 and neoplasm.